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Abstract: Aim: Primary human hepatocytes (PHHs) undergo dedifferentiation upon the
two-dimensional (2D) culture, which particularly hinders their utility in long-term in vitro studies.
Lipids, as a major class of biomolecules, play crucial roles in cellular energy storage, structure, and
signaling. Here, for the first time, we mapped the alterations in the lipid profile of the dedifferentiating
PHHs and studied the possible role of lipids in the loss of the phenotype of PHHs. Simultaneously,
differentially expressed miRNAs associated with changes in the lipids and fatty acids (FAs) of the
dedifferentiating PHHs were investigated. Methods: PHHs were cultured in monolayer and their
phenotype was monitored morphologically, genetically, and biochemically for five days. The lipid
and miRNA profile of the PHHs were analyzed by mass spectrometry and Agilent microarray,
respectively. In addition, 24 key genes involved in the metabolism of lipids and FAs were investigated
by qPCR. Results: The typical morphology of PHHs was lost from day 3 onward. Additionally,
ALB and CYP genes were downregulated in the cultured PHHs. Lipidomics revealed a clear increase
in the saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) containing lipids, but a
decrease in the polyunsaturated fatty acids (PUFA) containing lipids during the dedifferentiation
of PHHs. In line with this, FASN, SCD, ELOVL1, ELOVL3, and ELOVL7 were upregulated but
ELOVL2 was downregulated in the dedifferentiated PHHs. Furthermore, differentially expressed
miRNAs were identified, and the constantly upregulated miR-27a and miR-21, and downregulated
miR-30 may have regulated the synthesis, accumulation and secretion of PHH lipids during the
dedifferentiation. Conclusion: Our results showed major alterations in the molecular lipid species
profiles, lipid-metabolizing enzyme expression as wells as miRNA profiles of the PHHs during their
prolonged culture, which in concert could play important roles in the PHHs’ loss of phenotype.
These findings promote the understanding from the dedifferentiation process and could help in
developing optimal culture conditions, which better meet the needs of the PHHs and support their
original phenotype.
Int. J. Mol. Sci. 2019, 20, 2910; doi:10.3390/ijms20122910 www.mdpi.com/journal/ijms
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1. Introduction
Primary human hepatocytes (PHHs) are commonly used as the “gold standard” model system
to study liver physiology and disease, drug-induced liver injury, active drug transport mechanisms,
and drug-drug interactions [1–3]. In addition, hepatocytes handle many crucial metabolic functions of
the liver including the synthesis of fatty acids (FAs), cholesterol, cholesteryl esters, triacylglycerols
(TAGs), and phospholipids (PLs), and utilizing these lipids together with apolipoproteins produce
lipoprotein particles [4]. PHHs are sensitive to hepatitis C virus infection [5] and are able to express
cytochrome P450 enzymes and drug transporters at significantly higher levels than most hepatoma
cell lines such as HepG2 and Huh7 [6]. Since the availability of the PHHs is limited, scientists have
tried to utilize other sources such as rodent primary hepatocytes or stem cell-derived hepatic cells as
in vitro cell models. However, none of the so far developed hepatic models are yet as functional and
relevant as PHHs in mimicking the complex physiology of the liver.
Upon liver injury, hepatic cells are able to rapidly proliferate and regenerate even a large
area of the damaged organ [7]. Despite this extraordinary and unique feature, when hepatocytes
are isolated and cultured in vitro, they are unable to expand and progressively lose their unique
liver-specific functions [8,9], which typically limits their usability to a few days. This feature is
known as “dedifferentiation” and significantly hampers the application of the PHHs particularly
in long-term toxicity and xenobiotic biotransformation studies. It is known that the PHHs’ loss
of phenotype is primarily a consequence of fundamental gene expression changes and diminished
liver-enriched transcription factors triggered by the stress during isolation, disruption of the normal
tissue architecture [8,10]. On the other hand, the current culture systems are not able to restore
these phenotypical changes due to the lack of critical survival factors essential for liver-specific gene
expression [8]. 3D culture of PHHs alone or together with microfluidic systems and in coculture with
other cell types such as mesenchymal stem cells have been shown to improve the PHHs’ life span
and functionality [11–15]. However, the conventional 2D culture of PHHs is still the most common
approach due to its simplicity and low cost particularly for high-throughput studies. Although, in
this culture system, PHHs undergo progressive deterioration of their in vivo-like morphological and
functional phenotype [16].
The “-omics” approaches have been broadly utilized to map the changes in the transcriptome and
proteome of the dedifferentiating hepatocytes [17–21]. It has been shown that proteins responsible
for cytoskeletal remodelling as well as carbohydrate, amino acid and lipid metabolism networks are
differentially expressed in dedifferentiating hepatocytes [21]. In addition, a recent study showed
that energy production is decreased during the dedifferentiation through changes in the expression
of mitochondrial-associated proteins, particularly those involved in FA and lipid metabolism [18].
Furthermore, a transcriptomic study on noncoding RNAs showed that FA metabolism is among
the most affected pathways during dedifferentiation [22]. Despite the apparent importance of the
lipids in the process of dedifferentiation, surprisingly, no study has been conducted yet on mapping
the alterations in the lipid molecular species of the dedifferentiating hepatocytes. This has been
partially due to the technical challenges, but the field of lipidomics is now well advanced and the
approach using mass spectrometry can be utilized to better understand the role of molecular lipids
in various physiological states including dedifferentiation. Such detailed analysis is required since
mammalian cells produce thousands of lipids with various organelle-specific structural and functional
roles. In addition, cells synthesize hundreds of proteins to control the lipid metabolism and their
trafficking and secretion [23]. Therefore, an in-depth portrait of the temporal changes in the lipid profile
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and the associated genes and microRNAs (miRNAs) of the dedifferentiating hepatocytes is required to
understand the complex protein-lipid interplay during the dedifferentiation process. With this new
knowledge, we can optimize culture conditions and thereby improve both the phenotype and life span
of the cultured PHHs.
Here, for the first time, we studied the alterations in the lipidome of the dedifferentiating
primary human hepatocytes. To allow unrestricted dedifferentiation, PHHs were cultured in confluent
2D monolayer and their morphology, liver-specific gene expression, and function were monitored
during the five days in culture. Most importantly, the lipidome changes in PHHs together with the
alterations in the enzymes metabolizing FAs and lipids were studied during the dedifferentiation
process. As miRNAs have been shown to be one important driver of hepatic dedifferentiation [22],
alongside lipidomic studies, the temporal changes in the miRNA profile of the dedifferentiating PHHs
were also investigated.
2. Results
2.1. The Morphology, Gene Expression, and Functionality of PHHs
PHHs remained viable and confluent throughout the five days in the culture. However, they
started to lose their characteristic hepatocyte morphology from day 3 onward and at day 5, cells had
completely lost their typical polygonal structure and exhibited a flattened appearance with weakly
defined cell-to-cell borders (Figure 1A) which implied that the PHHs were dedifferentiating.
Using qPCR, the expression of three liver-specific genes was assessed in the dedifferentiating
PHHs (Figure 1B). FOXA2 expression was downregulated by 5-fold at day 1 compared to day 0 and
its expression remained low until day 5. Similar to FOXA2, the expression of ALB was dramatically
downregulated by 58-fold at day 1 compared to day 0 and remained low afterwards. The expression of
AFP fluctuated in the cultured PHHs and, depending on the time point, its level was 10- to 40-fold
higher than that in our control sample, hLTR.
In order to assess the functionality of the PHHs at the gene level, the expression of four of
the CYP isoforms known to be important in drug metabolism, lipid homeostasis, and cholesterol
biosynthesis [24–26] was evaluated in the dedifferentiating PHHs (Figure 1B). CYP1A2 was
downregulated by about 120-fold after the PHHs were cultured for one day. Similarly, CYP7A1
and CYP51A1 were both downregulated by approximately 2- and 3-fold during the first day of culture.
The expression of CYP3A4, was downregulated already before the culture since it’s expression levels at
day 0 was 18-fold lower than that in the reference hLTR sample. Interestingly, the expression of all four
CYP genes was slightly recovered either at day 2 or day 5 of the cell culture.
The functionality of the PHHs was assessed also biochemically by measuring the secreted TAG,
albumin, and urea in the medium of the cultured PHHs at day 2 and 5. No changes were observed in
the ability of the PHHs to secrete TAG and urea between day 2 and day 5 (Figure 1C). Interestingly
however, the amount of albumin secreted by PHHs at day 5 had increased by 55% compared to
its amount at day 2, which correlated well with our observation from the expression of ALB at the
gene level.
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Figure 1. Evaluation of the morphology and functionality of primary human hepatocytes (PHHs) 
during the course of dedifferentiation. (A) Phase contrast images showing the morphology of the 
PHHs at days 1, 2, and 5 of the culture. The scale bar represents 200 µm. (B) qPCR analysis of FOXA2, 
ALB, AFP, CYP1A2, CYP3A4, CYP7A1 and CYP51A1 genes at days 0, 1, 2, and 5. The gene expression 
data for FOXA2, ALB, and AFP was normalized to housekeeping gene, GAPDH, and CYP genes were 
normalized to both GAPDH and B2M. The values are presented relative to the human liver total RNA 
(hLTR) sample. Each sample was run in technical triplicate and bars represent mean ± SD of three 
biological replicates. (C) Biochemical analysis of the conditioned media of the PHHs for secreted 
triacylglycerol (TAG), albumin, and urea at day 2 and 5 of the culture. Values are presented per well, 
per 24 h. Bars represent mean ± SD of at least three biological replicates. 
Using qPCR, the expression of three liver-specific genes was assessed in the dedifferentiating 
PHHs (Figure 1B). FOXA2 expression was downregulated by 5-fold at day 1 compared to day 0 and 
its expression remained low until day 5. Similar to FOXA2, the expression of ALB was dramatically 
Figure 1. Evaluation of the morphology and functionality of primary human hepatocytes (PHHs)
during the course of dedifferentiation. (A) Phase contrast images showing the morphology of the
PHHs at days 1, 2, and 5 of the culture. The scale bar represents 200 µm. (B) qPCR analysis of FOXA2,
ALB, AFP, CYP1A2, CYP3A4, CYP7A1 and CYP51A1 genes at days 0, 1, 2, and 5. The gene expression
data for FOXA2, ALB, and AFP was normalized to housekeeping gene, GAPDH, and CYP genes were
normalized to both GAPDH and B2M. The values are presented relative to the human liver total RNA
(hLTR) sample. Each sample was run in technical triplicate and bars represent mean ± SD of three
biological replicates. (C) Biochemical analysis of the conditioned media of the PHHs for secreted
triacylglycerol (TAG), albumin, and urea at day 2 and 5 of the culture. Values are presented per well,
per 24 h. Bars represent mean ± SD of at least three biological replicates.
2.2. Alterations in the Lipid Profile of the PHHs
The lipid profile in the dedifferentiating PHHs was studied by mass spectrometry and a total of
139 molecular species spanning 19 cholesteryl esters (CEs), 16 ceramides, 10 diacylglycerols (DAGs),
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7 globotriaosylceramides (Gb3s), 9 glucosyl/galactosylceramides (Glc/GalCers), 7 lactosylceramides
(LacCers), 2 lyso-phosphatidylcholines (LPCs), 7 lyso-phosphatidylethanolamines (LPEs),
1 lyso-phosphatidyl glycerol (LPG), 3 lyso-phosphatidylinositols (LPIs), 1 lyso-phosphatidylserine
(LPS), 30 phosphatidylcholines (PCs), 7 phosphatidylethanolamines (PEs), 3 phosphatidylinositols
(PIs), and 17 sphingomyelins (SMs) were detected in the cultured PHHs at days 0, 1, 2, and 5 (Table
S2). Our data showed that the levels of sphingolipids (SLs) increase, but the levels of phospholipids
(PLs) decrease in the dedifferentiating PHHs (Figure 2A). In fact, the total concentration of ceramide,
LacCer, Glc/GalCer, and Gb3 increased in PHHs by 4.8-, 5.3-, 10.3-, and 4-fold, respectively from day 0
to day 5. On the other hand, the total concentration of PE and PI decreased by about 1.5- and 2-fold
respectively, from day 0 to day 5. The total PC remained relatively constant during the culture of the
PHHs. The total CE content was reduced in PHHs-d1 by almost 10-fold compared to PHHs-d0 and its
concentration remained low during the rest of the culture. The total amount of the DAG fluctuated
in PHHs.
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Figure 2. Alterations in the lipid profile of the PHHs during the dedifferentiation. Lines describe the 
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sphingolipid (SL) species, and (C,D) molecular phospholipid (PL) and diacylglycerol (DAG) species 
detected in PHHs at days 0, 1, 2, and 5; ’d’ represents days in culture. Panel C shows the PL molecular 
species that decreased, and panel D the species that increased during the dedifferentiation. Bars in A 
represent mean ± SD of three biological replicates. The detailed values of lipidomics is provided in 
the Table S2. CE = cholesteryl ester, Cer = ceramide, DAG = diacylglycerol, Gb3 = 
globotriaosylceramide, Glc/GalCer = glucosyl/galactosylceramide, LacCer = lactosylceramide, PC = 
phosphatidylcholine, PE = phosphatidylethanolamine, PI = phosphatidylinositol, SM = 
sphingomyelin. 
Monitoring the individual molecular species in PHHs during the culture period demonstrated 
that the concentration of almost all molecular SL species was increasing over time, particularly 
between day 2 and day 5 (Figure 2B). The only exceptions were Glc/GalCer d18:1/23:0, SM d18:0/23:0, 
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The second group largely consisted of SFAs and/or monounsaturated FAs (MUFAs), and the PUFA 
chains found in this group of lipids were restricted to the 20:3 and 20:4 chains. The concentrations in 
this group, in contrast to the first group, were mainly increasing between day 2 and day 5 (Figure 
2D). 
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Figure 2. lt rations in the lipid profile of the PHHs during the dediffere tiation. Lines describe the
detected concentratio (pmol/µg total protein) of (A) different lipid classes, (B) molecular sphingolipid
(SL) species, and (C,D) molecular phospholipid (PL) and diacylgl cerol (DAG) species detected
in PHHs at days 0, 1, 2, and 5; ’d’ represents days in culture. Panel C shows the PL molecular
species that decreased, and panel D the species that increased during the dedifferentiation. Bars in A
represent mean ± SD of three biological replicates. The detailed values of lipidomics is provided in the
Table S2. CE = cholesteryl ester, Cer = ceramide, DAG = diacylglycerol, Gb3 = globotriaosylceramide,
Glc/GalCer = glucosyl/galactosylceramide, LacCer = lactosylceramide, PC = phosphatidylcholine,
PE = phosphatidylethanolamine, PI = phosphatidylinositol, SM = sphingomyelin.
Monitoring the individual molecular species in PHHs during the culture period demonstrated that
the concentration of almost all molecular SL species was increasing over time, particularly between day
2 and day 5 (Figure 2B). The only exceptions were Glc/GalCer d18:1/23:0, SM d18:0/23:0, SM d18:1/23:0,
SM d18:1/23:1, and SM d18:1/26:2. Interestingly, h increase was more pron unced in SLs containing
long-chain FAs (LCFAs, C16-22) compared to those SLs containing very-long-chain FAs (VLCFAs,
C22-26).
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The concentration of PL molecular species also showed temporal changes, and based on the
alterations in their concentrations between day 2 and day 5, the PLs could be divided into two groups
(Figure 2C,D). In the first group, the species were mainly composed of polyunsaturated FAs (PUFAs,
specially 18:2) or highly unsaturated FAs (HUFAs, with 4–6 double bonds) coupled with a saturated
FA (SFA). The concentrations in this group were mainly decreasing from day 2 to day 5 (Figure 2C).
The second group largely consisted of SFAs and/or monounsaturated FAs (MUFAs), and the PUFA
chains found in this group of lipids were restricted to the 20:3 and 20:4 chains. The concentrations in
this group, in contrast to the first group, were mainly increasing between day 2 and day 5 (Figure 2D).
2.3. Alterations in the Lipid Metabolism-Related Genes
Several genes related to the synthesis of SLs were evaluated by qPCR in the dedifferentiating
PHHs (Figure 3). Ceramide synthesis is orchestrated by a family of six CerSs encoded by CERS1-CERS6
(Figure 4A). CERS1 and CERS5 were upregulated by 1.5- and 3-fold, respectively, in PHHs-d1 compared
to PHHs-d0. CERS1, however, was gradually downregulated while CERS5 remained upregulated
until the end of the culture. In contrast to CERS1 and CERS5, CERS4 was downregulated by 3-fold in
PHHs-d1 and remained relatively constant afterwards. The expression of CERS6 was upregulated by
2-fold in PHHs-d2 compared to PHHs-d0. CERS2 was expressed relatively constant throughout the
entire culture.
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Figure 3. qPCR analysis of key genes involved in the metabolism of sphingolipids (SLs) studied
in PHHs during their five days in the culture. The expression of CERS1, CERS2, CERS4, CERS5,
CERS6, AS H1, A AH2, SGMS1, SGMS2, SMPD1, and UGCG genes in PHHs at time points day 0, 1, 2,
and 5. The expression of each gene was normalized to both GAPDH nd B2M as endogenous controls.
The values are present d relative to the hLTR sample. Each s mple was run in technic l triplicate and
bars represent mean ± SD of three biological replicates.
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culture, while ASAH2 was downregulated in PHHs by 9-fold after one day in the culture. The 
expression of ASAH2 remained low until day 5. On the other hand, the expression of SGMS1 and 
SGMS2 involved in the production of SM from ceramides were constantly upregulating and in PHHs-
d5, both SGMS1 and SGMS2 were expressed approximately 3-fold higher compared to their levels in 
PHHs-d0. SM is hydrolyzed by isoforms of sphingomyelinase (SMase) which produce 
phosphorylcholine and the intracellular effector ceramide. SMPD1 gene encodes a lysosomal acid 
sphingomyelinase and its expression remained constant during the cell culture of the PHHs. 
The UDP-glucose:ceramide glucosyltransferase (UGCG) gene encodes the enzyme which 
catalyzes the first glycosylation step in glycosphingolipid (GSL) biosynthesis. In the cultured PHHs, 
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Figure 4. ( ) Demonstrate a simplified pathway of sphingolipids (SLs) togeth r with the responsible
key gen olved in regulating the p thway. (B) Demonstrates a simplified pathways of de-novo
synthesis of fatty acids (FAs) as well as imported essential polyunsaturated FAs (PUFAs) together with
responsible genes involved in regulating the pathway (the figure was adapted from Kiamehr et al. [27]).
Ceramides are degraded to sphingosine and free FAs by ceramidases encoded by distinct genes like
ASAH1 and ASAH2 (Figure 4A). The expression of ASAH1 remained constant throughout the culture,
while ASAH2 was downregulat d in PHHs by 9-fold after one day in the cult re. The expression of
ASAH2 remained low until day 5. On the other hand, the expression of SGMS1 and SGMS2 involved
in the production of SM from ceramides were constantly upregulating and in PHHs-d5, both SGMS1
and SGMS2 were expressed approximately 3-fold higher compared to their levels in PHHs-d0. SM is
hydrolyzed by isoforms of sphingomyelinase (SMase) which produce phosphorylcholine and the
intracellular effector ceramide. SMPD1 gene encodes a lysosomal acid sphingomyelinase and its
expression remained constant during the cell culture of the PHHs.
The UDP-glucose:ceramide glucosyltransferase (UGCG) gene encodes the enzyme which catalyzes
the first glycosylation step in glycosphingolipid (GSL) biosynthesis. In the cultured PHHs, UGCG
was upregulated by 6-fold at day 1 compared to day 0 and remained upregulated during the rest of
the culture.
2.4. Alterations in FA Metabolism-Related Genes
FA desaturas (FADS) inserts double bo ds o pre-existing PUFA precursors (Figure 4B). In our
study, FADS1 remained unchanged and FADS2 were upregulated by almost 3-folds at day 5. The genes
related to the elongation of very- long-chain fatty acids (ELOVL) work in sequence with the desaturases
and are essential for the metabolism of saturated or unsaturated LCFAs and VLCFAs (Figure 4B).
ELOVL1, ELOVL3, and ELOVL7 are involved in the elongation of saturated FAs while ELOVL2 and
ELOVL5 are mainly involved in elongation of unsaturated FAs. We observed that ELOVL1 was
upregulated in PHHs-d1 by 4-fold compared to the expression level in PHHs-d0, and its expression
remained upregulated until day 5. ELOVL3 was constantly upregulated from day 0 to day 5. ELOVL7
was expressed at low levels on days 0–2 but was upregulated by 2-fold at day 5 when compared to
the level found on day 2. On the other hand, ELOVL2, was downregulated in PHHs-d1 by 3-fold
compared to PHHs-d0 and remained low afterwards. Genes active in the beginning of the process of
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de novo synthesis of FAs such as FA synthase (FASN), Stearoyl-CoA desaturase (SCD), and ELOVL6
showed the same pattern of expression and were downregulated in the beginning of the culture but
were upregulated and recovered to their original expression towards the end of the culture (Figure 5A).
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Figure 5. Real-time qPCR analysis of genes involved in the metabolism of fatty acids (FAs). (A) and
glucose homeostasis (B) studied in dedifferentiating PHHs. The expression of (A) FASN, SCD, FADS1,
FADS2, ELOVL1, ELOVL2, ELOVL3, ELOVL5, ELOVL6, and ELOVL7 and (B) GCK, PKLR, and PCK1 at
time points day 0, 1, 2, and 5. The expression of each ge e was normalized to both GAPDH and B2M as
endo enous c ntrols. The values are pres nted relative to the hLTR ample. Each sample was run in
technical triplicate and bars represent mean ± SD of three biological replicates.
2.5. Alterations in the Genes Related to Glucose Homeostasis
Since the lipid metabolism in hepatocytes is highly affected by glucose homeostasis (Figure 4B),
we studied the three key genes involved in glycolysis (GCK (encoding glucokiase) and PKLR
(encoding liver-type pyruvate kinase)) and gluconeogenesis (PCK1 (encoding phosphoenolpyruvate
carboxykinase, thus also known as PEPCK)) of the liver (Figure 5B). All three genes, GCK, PKLR,
and PCK1, were downregulated in PHHs after one day in the culture. The expression of both GCK
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and PCK1 was further downregulated in PHHs-d2 and PHHs-d5. PKLR however, was upregulated in
PHHs-d2 and recovered its original level of expression at day 5 of the culture.
2.6. Alterations in the miRNA Profile of the PHHs
In total, 382 miRNAs were detected in the cultured PHHs at time points day 0, 1, 2, and 5 (Table S3).
A heatmap was prepared from all 382 miRNAs detected and according to their expression pattern,
miRNAs could be divided into five distinct clusters (Figure 6A,B). Our analysis showed that 23 miRNAs
were upregulated and 22 miRNAs were downregulated in PHHs-d5 compared to those in PHHs-d0.
The miR-34a, miR-27a, and miR-1246 were the most upregulated and miR-575, miR-4741, and miR-8069
were the most downregulated miRNAs in PHHs-d5. A separate heatmap was prepared from the 30
most differentially expressed miRNAs (Figure 6C). Several differentially expressed miRNAs (shown in
red of Figure 6C) have been already associated with functionality or regulating the lipid metabolism of
the cells (see Discussion Section).
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Figure 6. Influence of prol nged culture of PH s on their miRNAs expression detected by microarrays.
(A) Unsupervised hierarch cal clustering of miRNAs using Eucledia distance an complete linkage in
the samples. Columns indicate the days of the culture. The expressions of the miRNAs are row-scaled
(by time point) and colour coded with blue indicating decreased and red indicating increased expression.
miRNAs are clustered in five distinct groups according to their expression pattern marked with coloured
boxes and numbers on the left side of the heatmap. The detailed list of miRNAs belonging to each
cluster is provided in the Table S3. (B) To better illustrate the alterations of miRNAs presented in panel
A, box-plots are prepared for each individual cluster at time points day 0, day1, day 2, and day 5. Each
box-plot represents the average row-scaled expression of all miRNAs in that specific time point and the
bars represent the mean ± SD of the collective miRNAs. Colours on the bottom of each plot is matching
the colour of the clusters in the panel A. The numbers of miRNAs included in each cluster are shown in
their respective coloured area. (C) Heatmap representing the expression changes of top 30 miRNAs in
cultured PHHs on days 1, 2, and 5. Red font colour indicate the miRNAs already associated with the
functionality and lipid metabolism of PHHs.
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3. Discussion
Lipid and FA synthesis pathways are dramatically affected during the process of dedifferentiation
in cells [18,21,22]. However, the exact alterations and their possible role in the rapid dedifferentiation
of the PHHs is not yet understood. Here, for the first time, we have performed a comprehensive
lipidomic and lipid-related gene analysis on dedifferentiating PHHs alongside with miRNA analysis.
We observed major alterations in both lipid and miRNA profiles of the PHHs during their prolonged 2D
culture. Furthermore, de novo synthesis of SFAs and MUFAs was upregulated while PUFA synthesis
seemed to be downregulated in the dedifferentiating PHHs, which was clearly mirrored in the increased
levels of SLs and MUFA containing PLs and decreased levels of PUFA containing PLs.
PHHs remained viable during the culture, however, the liver-specific functions, as indicated
by ALB and CYP1A2 expression were deteriorating rapidly after plating. In addition, CYP3A4
and CYP7A1 were expressed already in PHHs-d0 considerably lower than those in freshly isolated
liver samples (hLTR), indicating the diminished expression of those genes even before plating and
possibly during the isolation and perfusion process. It is known that dedifferentiation can be triggered
already during the isolation process, when organized and polarized cellular architecture of the liver
is disrupted and ischemia-perfusion injury occurs. As a result, liver-enriched transcription factors
and CYP enzymes become downregulated and hepatocytes rapidly deteriorate [8,10,28]. Interestingly,
the downregulated ALB and CYP genes were slightly upregulated after 2 or 5 days in culture, which
may imply the partial adaptation of the PHHs to the 2D culture environment [8,29]. Dedifferentiation
is a complex, differentially controlled, and active process [18] and while the mRNA expression related
to some enzymes become downregulated, the transcription of others might stay unchanged or even
over-expressed during the prolonged culture of PHHs. However, it should be recalled that the
fluctuations in mRNA levels only indicate the prevailing metabolic responses of the cells but the
patterns do not necessarily correspond to the fluctuations in the steady-state cellular contents of the
functional proteins or enzymes.
The lipidomic analysis showed that the concentration of almost all SL species increased in
the dedifferentiating PHHs, and most increases were detected in Glc/GalCer species. SLs have
been classically associated to cell permeability; however, their roles in intercellular communication
and cell signaling are now well recognized. SLs are involved in the regulation of cell growth,
differentiation, senescence, necrosis, proliferation, and apoptosis [30]. The metabolism of SLs is a
complex process consisting of multiple metabolic pathways with ceramide acting as a central key
molecule [31]. Ceramide can be further metabolized to SM or GlcCer, the first step in the metabolism
of the glycosphingolipid (GSL) family. GSLs are involved in various cellular events such as signaling,
trafficking, and cellular interactions [32]. To better understand the alterations in SLs, we further studied
the key genes involved in the metabolism of SLs and we observed that several genes such as SGMS1
and UGCG, involved in the synthesis of SLs, were upregulated and simultaneously, ASAH2 involved
in the degradation of SLs was downregulated in the dedifferentiated PHHs. These findings were in
line with our lipidomics observations of elevated SL contents. In addition, we detected a temporal
upregulation of CERS1 (synthesizing C18 ceramides) and upregulation of CERS5 (synthesizing C16
ceramides), but a downregulation of CERS4 (synthesizing C18-20 ceramides) in the cultured PHHs.
In agreement with this changes, the ceramide species with the 16:0 or 18:0 acyl chain showed the most
increases during the process of dedifferentiation. Ceramide synthesis is orchestrated by a family of
six CerSs (CerS1-CerS6), each of which produce ceramides with distinct FA chain lengths and degree
of unsaturation [33]. The FA composition of a ceramide determines its biological function [33,34]
and different ceramides are known to be involved in regulating the balance between cell death and
survival [35]. The upregulation of CERS1 and CERS5 but downregulation of CERS4 in dedifferentiating
PHHs may be attributable to the activation of a pro-survival or anti-apoptotic pathway in PHHs. It is
known that many of the earliest changes during the dedifferentiation are associated to cell survival or
maintenance of homeostatic functions [18]. These alterations could act as a double-edged sword, on one
hand preventing apoptosis, while on the other hand, playing a critical role in the loss of liver-specific
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functions. Therefore, we think that the alteration in the expression of CerSs could play an important
role in both survival and dedifferentiation of the PHHs.
Our study showed that the concentration of SM species increased during the dedifferentiation
and this increase was concurrent with upregulation of both SGMS1 and SGMS2 expression. SMS1
and SMS2 enzymes are, to current knowledge, the most responsible for SM de novo synthesis [36].
Approximately two thirds of cellular SM amount is located on the plasma membrane and about 65%
of membrane SM is located in lipid rafts [37]. Lipid rafts are specialized microdomains of plasma
membrane enriched with very-long-chain and saturated SLs, unlike the surrounding bulk membrane,
which contains unsaturated PLs [38,39]. Therefore, our findings implicate that the organization of the
cell membrane and dynamics of the lipid rafts are altered during the dedifferentiation, which would
critically affect cell signaling, membrane trafficking, as well as membrane fluidity and permeability,
ultimately resulting in compromised cellular functionality.
FAs are building block of lipids, therefore, we also studied the expression of key genes involved in
the metabolism of FAs. A list of studied lipid and FA metabolism related genes and their function has
been summarized in Table 1. We observed an upregulation in the de-novo synthesis of SFAs and MUFA
synthesis pathways but a downregulation in the production of PUFAs in the dedifferentiating PHHs.
In the cytoplasm, acetyl-CoA is carboxylated to malonyl-CoA, which is used as a precursor by FAS
enzyme to synthesize palmitic acid (16:0 FA) [40]. The 16:0 is then elongated by ELOVL members in
the ER to generate LCFAs (>16 carbon). The LCFAs are desaturated by SCD to produce MUFAs. These
MUFAs are utilized by the cells for the production of e.g., PLs and TAGs [41]. FASN, ELOVL6, and SCD
showed the same pattern of expression, suggesting that they regulated the de novo FA synthesis
in concert during the prolonged culture of the PHHs and interestingly, this pattern of expression
was mirrored in the levels of the PL species containing FA 18:1 (e.g., PC 18:1/18:1 and PI 18:1/18:1)
(Figure 2D). ELOVL1, ELOVL3, ELOVL6, and ELOVL7 have a putative role in the elongation of SFAs
and MUFAs, and ELOVL2 and ELOVL5 are known as PUFA elongases [42]. ELOVL1 and ELOVL3 were
upregulated during the dedifferentiation of the PHHs, confirming our observed increase in the levels
of SFAs and MUFAs. On the other hand, ELOVL2 became downregulated in the dedifferentiating
PHHs, in line with our observations of reduced concentrations of PL species containing a very-long
chain PUFA chain. The PHHs synthesize the very-long chain and highly unsaturated FAs from the
PUFA precursors (FAs 18:2 or 18:3) which are taken up from the culture medium. Reduced levels
of PUFAs, but increased levels of MUFAs in the dedifferentiated PHHs may imply that their ability
to uptake the 18:2 precursor, available abundantly in their medium was altered due to membrane
structure modifications. This could drive PHHs to compensate their PUFA deficiency by increasing the
production of MUFAs [43].
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Table 1. List of key genes involved in the lipid and fatty acid metabolism and their function.
Genes Functions References
CERS1, CERS2, CERS4,
CERS5, CERS6
Encoding enzymes that catalyze the synthesis of ceramides from
sphingoid base and acyl-CoA substrates. [33,44,45]
ASAH1, ASAH2 Encoding acid (ASAH1) and neutral (ASAH2) ceramidases thatdegrade ceramides to sphingosine and free fatty acids (FAs). [29]
SGMS1, SGMS2 Synthesis of sphingomyelin from ceramides and crucial in ceramideand sphingomyelin homoeostasis. [46]
SMPD1 Encoding a lysosomal acid sphingomyelinase hydrolyzingsphingomyelin to ceramide. [47]
UGCG Encoding the enzyme that catalyzes the first glycosylation step inglycosphingolipid biosynthesis. [48]
FADS1, FADS2
Encoding for the enzymes inserting double bonds to pre-existing
polyunsaturated fatty acid (PUFA) precursors. Critical for the
synthesis and regulation of PUFAs.
[49]
ELOVL1, ELOVL2,
ELOVL3, ELOVL5,
ELOVL6, ELOVL7
Encoding enzymes that function in concert with FADSs and
determine the rate of overall fatty acid elongation. ELOVL1,
ELOVL3, ELOVL6, and ELOVL7 are involved in elongation of
saturated and monounsaturated FAs, while ELOVL2 and ELOVL5
are involved in elongation of PUFAs. ELOVL5 also elongates some
monounsaturated FAs, such as palmitoleic acid (FA 16:1).
[50]
FASN Encoding the enzyme that determines the de-novo synthesis of FAsby synthesising palmitic acid (FA 16:0). [40]
SCD Encoding a rate-limiting enzyme in the cellular synthesis ofmonounsaturated FAs from saturated FAs. [43]
FAs are a major source of energy, regulated by a variety of factors acting in concert to maintain the
energy homeostasis within the cells. Glucose—a precursor for Acetyl-CoA—is one main regulator and
its metabolism is controlled by various pathways including glycolysis and gluconeogenesis [51,52].
Downregulation of both GCK and PCK1 in dedifferentiating PHHs points towards a decrease
in glycolysis and gluconeogenesis respectively, resulting in the lower production of Acetyl-CoA,
a precursor for synthesis of FAs. Despite this, we observed that de novo FA synthesis increased
in dedifferentiated PHHs. This may imply that PHHs utilized Acetyl-CoA produced from other
precursors than glucose such as glutamine [52] available in the culture medium. Nevertheless, the
deterioiration of in vivo-like morphological and functional phenotype of PHHs is a very complex
process, which likely involves also other regulatory factors than those investigated in the current study.
For instance, the fundamental integration of hepatic glucose and ipid metabolism, which employs
counteracting SREBP-1 and ChREBP signaling, could also be affected in the dedifferentiation process
of PHHs [53].
Recently, miRNAs were shown to play important roles in the PHHs’ loss of phenotype [22,54].
In addition, emerging evidence shows that miRNAs are important regulators of lipoprotein formation
and secretion, lipid synthesis, and FA oxidation [55]. Therefore, alongside lipidomics, we performed
miRNA analysis on dedifferentiating PHHs to identify the miRNAs that possibly regulate the lipid
changes during the dedifferentiation. We mainly focused on miRNAs with an established role in
the regulation of lipid and FA metabolism or linked to the functionality of the cells and interestingly,
we identified several miRNAs such as miR-34a, miR-23a, miR-27a (included in cluster 2), miR-21
(included in cluster 4), and miR-30c and miR-122 (included in cluster 1) among up- or downregulated
miRNAs [55–59]. The miR-34a was the most upregulated miRNA and is among the most studied
miRNAs with multiple known roles in the regulation of cell cycle, differentiation, migration, and
apoptosis [55]. In addition, miR-34a is one of the regulators of HNF4α [58]. HNF4α positively regulates
the expression of bile acid-synthesizing enzymes such as CYP7A1 [60]. Furthermore, miR-34a negatively
regulates retinoid X receptor alpha (RXRα) resulting in decreased induction of CYP26 family and
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CYP3A4 [61]. Moreover, it has been shown that miR-34a targets Sirtuin 1 (SIRT1), which regulates a series
of genes and proteins involved in lipid and glucose metabolism [62–64]. Another upregulated miRNA
in the dedifferentiated PHHs was miR-23a, which is known to suppress gluconeogenesis through
PGC-1α and G6PC, leading to decreased glucose production in the hepatic cells [65,66]. Therefore, the
upregulation of miRNa-34a and/or miRNA-23a could be associated with the downregulation of GCK,
PCK1, and CYP genes, and the loss of functionality of the dedifferentiated PHHs.
Similar to miR-34a, miR-27a is also shown to target RXRα. In addition, it can regulate ATP-binding
cassette transporter A1 (ABCA1) [55,67]. Overexpression of miR-27a has been shown to accelerate
adipolysis and repress lipid storage in the cells [55]. In addition, miR-27a inhibits the expression of
FASN, SCD1, sterol regulatory element-binding proteins (SREBP-1 and SREBR-2), PPARα and PPARγ,
APOA1, APOB100, and APOE3 [56,68]. Therefore, it has been suggested that miR-27 may regulate
the metabolism of lipids by increasing lipid secretion and reducing lipid synthesis in the cells [55].
In our study, miR-27a was constantly upregulated in the dedifferentiating PHHs which occurred
simultaneously with the downregulation of both FASN and SCD in PHHs-d1 and PHHs-d2, but not in
PHHs-d5 where the expression of those genes was upregulated. This suggests that other miRNAs could
be involved in the regulation of the FASN and SCD in PHHs. miR-21 (included in cluster 4) was another
miRNA which showed constant upregulation in dedifferentiating PHHs. miR-21 has shown to target
fatty acid-binding protein 7 (FABP7) and blocking C 18:0-induced intracellular lipid accumulation [69].
In addition, miR-21 directly targets PPARα and plays a role in development of steatosis by inhibition
of PPARα-mediated FA uptake and lipid oxidation [59,70]. Together with liver X receptor (LXR) and
insulin agonists, PPARα agonists can induce lipogenic gene expression such as FASN [71]. In addition,
it has been recently reported that miR-30c directly targets FASN, resulting in reduced TAG accumulation
in the cells [72]. In our study, miR-30c was downregulated in PHHs-d5 simultaneously with the
upregulation of FASN. In another study the microsomal triglyceride transfer protein (MTP), important
for lipoprotein formation, was found to be regulated by miR-30c [73]. Therefore, miR27a, miR21, and
miR-30c could be working together to regulate the synthesis, accumulation, and secretion of lipids
in PHHs during the process of dedifferentiation. Expectedly, miR-122 was also downregulated in
dedifferentiated PHHs. miR-122 is not only regarded as a hepatic-specific marker but also is the
first identified miRNA to regulate lipid metabolism [55]. miR-122 is also known to be essential for
maintaining the hepatocellular phenotype [74,75]. Interestingly, the phenotypic and morphological
loss of PHHs was concurrent with a steep reduction in the expression of miR-122 on day 5.
Taken together, this study provides novel findings on the possible roles of lipids, FAs, their
corresponding metabolising enzymes, and the miRNAs in the process of dedifferentiation. This data
may be applied to unravel the mechanisms behind the fast deterioration of the PHHs and developing
culture conditions that would better support the phenotype of the PHHs in the culture for long-term
studies. In addition, this knowledge could be utilized in the development of novel strategies for
improving protocols for differentiation and maturation of stem cell-derived hepatocytes.
4. Method and Materials
4.1. Cell Culture
Cryopreserved PHHs (Cat. No. HMCPIS, Lot. HU8210, 51-year-old Caucasian male) were
purchased from Gibco® and were thawed and plated according to the manufacturer’s instructions.
PHHs were cultured in monolayer on collagen-I-coated plates (CellAffixTM, AP Sciences Inc., Columbia,
MD, USA), 2.5 × 105 cells/cm2, and maintained in William’s E medium (A1217601, Gibco; without
L-glutamine) supplemented with cocktail B (CM 4000, Gibco; Durham, NC, USA, including ITS
(insulilne, transferine, selenium), GlutaMAXTM, BSA, and linoleic acid [18:2n-6] as the main FA
constituent with 89 mol%, as detected by gas chromatography in the batch used for this study) and
dexamethasone for up to 5 days. PHHs that were collected immediately after plating were considered
as samples day 0. PHHs were also collected at days 1, 2, and 5.
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4.2. Real-Time Quantitative PCR Analysis
RNA samples were collected (three biological replicate per time point) from PHHs at days 0, 1,
2, and 5 by RNeasy kit (Qiagen, Cat. No. 74106). cDNA was generated by High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Ref. No. 4368814, Vilnius, Lithuania) according to the
manufacturer’s instructions in the presence of RNase inhibitor. cDNA was multiplied either by Power
SYBR Green PCR Master Mix (Applied Biosystems, Cat. No. 4367659, Warrington, UK) and gene
specific primers (FOXA2, AFP, ALB) or Taqman Fast Advanced Master Mix (applied Biosystems, Ref.
No. 4444557, Austin, TX, USA) and gene specific TaqMan probes (CYP1A2, CYP3A4, CYP7A1, CYP51A1,
CERS1, CERS2, CERS4, CERS5, CERS6, ASAH1, ASAH2, SGMS1, SGMS2, SMPD1, UGCG, FASN,
FADS1, FADS2, SCD, ELOVL1, ELOVL2, ELOVL3, ELOVL5, ELOVL6, ELOVL7, GCK, PKLR, and PCK1)
using BioRad CFX384 Real Time PCR Detection System (Optic Module, Singapore). List of primers
and TaqMan assays used in this study are presented in Table S1a,b. Values from FOXA2, AFP, and
ALB were normalized to GAPDH and the rest to both GAPDH and B2M used as endogenous controls.
Relative quantification was calculated by ∆∆CT method using Bio-Rad CFX Manager software, version
3.1 (Hercules, CA, USA). Fold change 2 was considered as a cut off value when considering a gene to
be up- or downregulated.
First Choice® Human Liver Total RNA (hLTR, InvitrogenTM, Cat. No. AM7960) was purchased
from Ambion® and was used as a reference sample.
4.3. Triacylglycerol, Albumin, and Urea Secretion
At days 2 and 5 of the cell culture, PHHs were evaluated for their functionality using biochemical
assays (three to four biological replicates per time point). TAG, albumin, and urea content of the PHHs’
conditioned medium were determined, respectively, by triglyceride quantificaiton kit (BioVision Inc.,
Milpitas, CA, USA, Cat. No. K622-100), human albumin ELISA quantitation kit (Bethyl Laboratory,
Montgomery, TX, USA), and QuantiChromTM urea assay kit (BioAssay Systems, Hayward, CA, USA)
according to the manufacturers’ instructions. The results were then compared to the unconditioned
William’s E medium.
4.4. Lipid Mass Spectrometry
Lipids (glycerolipids, SLs, GSLs and CEs) were extracted from PBS-resuspended PHHs on days
0, 1, 2, and 5 (three replicates per time point) by a modified Folch lipid extraction, using chloroform,
methanol, and acetic acid for liquid-liquid extraction [76] employing a Hamilton Microlab Star system
(Hamilton Robotic AB, Kista, Sweden). Details of the extraction procedure have been published
before [77].
CE, DAG, and SM were analysed using the shotgun approach on a hybrid triple quadrupole/linear
ion trap mass spectrometer (QTRAP 5500) with nanoflow ion source (NanoMate, Advion Biosciences
Inc., Ithaca, NY, USA) as described by Heiskanen et al. [78]. Molecular species were analyzed in positive
ion mode using lipid class-specific precursor ion or neutral loss scans [79,80]. Ceramide, Glc/GalCer,
LacCer, Gb3, PC, PE, and PI were analysed using the targeted approach by ultra-high-pressure liquid
chromatography-mass spectrometry (UHPLC-MS) [81]. An analytical Acquity BEH C18, 2.1 × 50
mm column with a particle size of 1.7 µm (Waters, Milford, MA, USA) was used with the mobile
phases containing 10 mM ammonium acetate in water with 0.1% formic acid (solvent A), and 10 mM
ammonium acetate in acetonitrile:isopropanol (4:3, v/v) containing 0.1% formic acid (solvent B). Both
SLs and PLs were analyzed on a hybrid triple quadrupole/linear ion trap mass spectrometer (5500
QTRAP) equipped with an UHPLC system (CTC HTC PAL autosampler and Rheos Allegro pump
or Shimadzu Nexera X2) using a multiple reaction monitoring based method in positive ion mode
for sphingolipids and negative ion mode for molecular PLs. Identified lipids were quantified by
normalizing against their respective internal standard [82] and total protein concentrations in the cell
sample. The details for the procedure has been published before [83]. Total protein concentrations
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were determined using the Micro BCA™ Protein Assay Kit (Thermo Scientific Pierce Protein Research
Products Cat. No. 23235, Rockford, IL, USA). Data processing was performed by MultiQuant,
LipidView (AB Sciex) software and SAS.
4.5. miRNA Analysis
For quantification of RNA eluates, Nanodrop ND-1000 Instrument was used (Thermo Fisher
Scientific, Darmstadt, Germany). Quality control was performed using Agilent 2100 Bioanalyzer and
the Nano or Pico RNA Kit depending on Nanodrop RNA concentration (Pico Chip: 50–5000 pg/µL;
Nano Chip: 5–500 ng/µL) according to the manufacturer’s instructions (Agilent Technologies, Santa
Clara, CA, USA). The expression profiles of all miRBase release v21 human miRNAs were determined
using Agilent Sureprint G3 Human miRNA (8 × 60 K) microarray slides. Each array targets 2549
microRNAs with 20 replicates per probe. RNA was labelled and hybridized using the Agilent’s miRNA
Complete Labeling and Hybridization Kit according to manufacturer’s protocol. After hybridization
for 20 h at 55 ◦C, the slides were washed twice and scanned using Agilent’s High Resolution Microarray
Dx Scanner. Scan images were transformed to raw text data using Feature Extraction Software (Agilent
Technologies, Santa Clara, CA, USA).
The signal to noise ratio (S/N) was set on 3 as a cut off value for the presence of miRNAs.
To normalize the data across different arrays, quantile normalization [84] was applied using the robust
multi-array average (RMA) algorithm [85]. All further analyses were based on these normalized and
background subtracted data. Log2 fold change 1 was applied as a cut off value for determining the up-
or downregulation of miRNAs in PHHs.
To find the expression patterns among miRNAs (presented in Figure 6), a complete linkage
hierarchical clustering was applied using Euclidean distance. The patterns were based in relative
expression to find similarities independent of the absolute expression intensity.
5. Conclusions
We identified alterations in the pathways of lipid and FA metabolism in the dedifferentiating
PHHs, which may play fundamental roles in PHHs’ loss of phenotype in the culture. Our results
suggest major modifications in the organization of the cellular membranes in the dedifferentiating
PHHs, which may greatly impair their function and the way they store energy or secrete lipids. These
alterations were concurrent with up- or downregulation of miRNAs with proven roles in the regulation
of lipid or FA synthesis. However, the complete elucidation of the association between miRNAs and
lipids during the dedifferentiating process remains to be further explored and validated.
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Abbreviations
CE cholesteryl ester
CerS ceramide synthase
DAG diacylglycerol
ELOVL fatty acid elongase
ER endoplasmic reticulum
FA fatty acid
FADS fatty acid desaturase
FASN fatty acid synthase
Gb3 globotriaosylceramide
GCK glucokiase
Glc/GalCer glucosyl/galactosylceramide
GSL glycosphingolipid
hLTR human liver total RNA
HUFA highly unsaturated fatty acid
LacCer lactosylceramide
LCFA long-chain fatty acid
miRNA microRNA
MUFA monounsaturated fatty acid
PC phosphatidylcholine
PE phosphatidylethanolamine
PCK1 phosphoenolpyruvate carboxykinase
PHH primary human hepatocyte
PI phosphatidylinositol
PKLR liver-type pyruvate kinase
PL phospholipid
PS phosphatidylserine
PUFA polyunsaturated fatty acid
qPCR quantitative PCR
RXRα retinoid X receptor alpha
SCD stearoyl-CoA desaturase
SFA saturated fatty acid
SL sphingolipid
SM sphingomyelin
SMS sphingomyelin synthase
TAG triacylglycerol
UGCG UDP-glucose ceramide glucosyltransferase
VLCFA very-long-chain fatty acid
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